IRCT20200105046010N9招募中未知
In- Vivo Bioequivalence study of Levodopa/Carbidopa/Entecapone tablet 200/50/200mg Fanda Pharma (Staparkin 200/50/200mg) with brand drugs (Stalevo 200/50/200mg Novartis, Germany) in Iranian healthy volunteers.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health ( liver , heart , kidney )
- •Body mass index (18-28 )
- •Informed consent
- •Age (18-60 )
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
Unknown
In-vivo Bioequivalence Study of Levodopa/Benserazide 125 mg HBS Capsules and Dispersible Tablets of The Test Drug (Norstor® 125 mg HBS Capsules and Dispersible Tablets, Pars Gita Darou, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N110Pars Gita Daru24
招募中
不适用
Comparative in vivo evaluation of 2 Levodopa/Benserazide 200/50 mg Tablet formulations.Parkinson's diseaseparkinson's disease.IRCT20180620040164N30Cosar pharmaceutical Co.24
已完成
1 期
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral AdministrationFasted StateNCT02116465Desitin Arzneimittel GmbH12
已完成
2 期
An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)Parkinson's DiseaseNCT00200447Molecular NeuroImaging3
招募中
不适用
enalidomide cap. 25mg Sobhan Oncology (LENASOB® 25mg), In-Vivo Bioequivalence in iranian healthy volunteer.In this study, the disease is not examined. Subject bioequivalence test and reference tablets Teriflunomide studied..IRCT20200105046010N26SOBHAN ONCOLOGY Pharmaceutical24